Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report
BackgroundA subset of cancer patients receiving monoclonal antibody PD-1/PD-L1 inhibitors may develop immune checkpoint inhibitor (ICI)-related neurological complications, such as ICI-related myasthenia gravis(MG)-myositis overlap syndrome and ICI-rela…